An open-label, multi-center, phase I/II study of ECI830 as a single agent and in combination with ribociclib and endocrine therapy in patients with advanced hormone receptor positive, HER2-negative breast cancer and advanced solid tumors (CECI830A12101)

Principal Investigator

Dr Simon Lord

Contact us

Email: orh-tr.earlyphasenurses@nhs.net

IRAS number

1011029